The decision to pause its investment in Britain came as AstraZeneca announced plans to spend $3.5bn (£2.7bn) expanding its US ...

Reading ‘Australia’s Pandemic Exceptionalism’ and this official response report is essential for anyone likely to have ...

This column, forecasting a Trump election win, last week expressed surprise so many news consumers remain loyal to media ...

The 868-page report of the official inquiry into Australia’s Covid-19 response, like the inquiry itself, is not fit for ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Controversy followed close on the heels of a recent study on the long-term safety of Covaxin, the Covid-19 vaccine developed by Bharat Biotech in collaboration ...

Where we succeeded, it was the result of good institutions and good decision-making. But that’s not to say we didn’t stumble.

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.

Chiropractors for RFK —Three appeals in a pod —The FDA shortage saga —The ghost of elections past And more! Join the conversation here.

A long negative candle was formed on the daily chart after the upside bounce of the last two sessions. The crucial overhead ...